The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO trial: Impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent

Victor L. Serebruany

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO trial: Impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent'. Together they form a unique fingerprint.

Medicine & Life Sciences